Personalized Ophthalmology Therapies Market Report 2026

Personalized Ophthalmology Therapies Market Overview

• Personalized Ophthalmology Therapies market size has reached to $3.23 billion in 2025 • Expected to grow to $6.22 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Rising Prevalence Of Chronic Vision Disorders Driving The Growth Of The Market Due To Increasing Diabetes Cases And Associated Eye Complications • Market Trend: Advancements In Single-Dose Intravitreal Gene Therapies Reducing Treatment Burden And Enhancing Long-Term Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Personalized Ophthalmology Therapies Market?

Personalized ophthalmology therapies refer to customized treatment approaches for eye diseases and vision disorders that are tailored to an individual patient’s unique genetic profile, molecular characteristics, lifestyle, and clinical condition. These therapies leverage advances in genomics, biomarker analysis, imaging, and precision medicine to optimize drug selection, dosage, or surgical intervention for conditions such as age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and inherited retinal diseases. The main types of personalized ophthalmology therapies include gene therapy, cell therapy, pharmacogenomics, targeted drug delivery, and others. Gene therapy in ophthalmology involves introducing or altering genetic material within a patient's cells to treat eye diseases caused by genetic mutations. It is used for various indications such as age-related macular degeneration, diabetic retinopathy, glaucoma, retinitis pigmentosa, and others by several end users, including hospitals, specialty clinics, research institutes, and others.

What Is The Personalized Ophthalmology Therapies Market Growth Forecast?

The personalized ophthalmology therapies market size is expected to see rapid growth in the next few years. It will grow to $6.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to increasing approvals of gene and cell therapies, rising investments in precision ophthalmology research, expansion of personalized treatment protocols, growing adoption of advanced drug delivery platforms, increasing demand for long-term vision preservation solutions. Major trends in the forecast period include increasing development of gene-based ophthalmic therapies, rising adoption of biomarker-guided treatment approaches, growing use of advanced retinal imaging for therapy selection, expansion of targeted drug delivery systems, enhanced focus on personalized disease management.

Global Personalized Ophthalmology Therapies Market Segmentation

1) By Therapy Type: Gene Therapy, Cell Therapy, Pharmacogenomics, Targeted Drug Delivery, Other Therapy Types 2) By Indication: Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Retinitis Pigmentosa, Other Indications 3) By End User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users Subsegments: 1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, CRISPR Or Cas9-Based Gene Editing 2) By Cell Therapy: Stem Cell Therapy, Retinal Pigment Epithelial (RPE) Cell Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy 3) By Pharmacogenomics: Drug Response Testing, Genetic Biomarker-Based Therapy, Personalized Drug Dosing 4) By Targeted Drug Delivery: Nanoparticle-Based Delivery, Liposomal Drug Delivery, Hydrogel-Based Delivery Systems 5) By Other Therapy Types: RNA-Based Therapy, Antisense Oligonucleotide Therapy, Peptide-Based Therapy

What Is The Driver Of The Personalized Ophthalmology Therapies Market?

The growing prevalence of chronic vision disorders is expected to propel the growth of the personalized ophthalmology therapies market going forward. Chronic vision disorders are persistent eye diseases that progressively impair vision and often require ongoing management over an extended period. Chronic vision disorders are rising due to the increasing prevalence of diabetes worldwide, which leads to complications such as diabetic retinopathy that progressively damage the eyes over time. Personalized ophthalmology therapies benefit chronic vision disorders by creating treatment plans tailored to an individual’s unique genetic and molecular profile, which enhances treatment effectiveness and helps slow the progression of the disease. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, if effective measures are not implemented, cases of diabetic retinopathy are projected to rise by 72%, while cataract cases are expected to grow by 87% by 2050. Therefore, the growing prevalence of chronic vision disorders is driving the growth of the personalized ophthalmology therapies industry.

Key Players In The Global Personalized Ophthalmology Therapies Market

Major companies operating in the personalized ophthalmology therapies market are Roche Holding AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Genentech Inc., Bausch + Lomb Corporation, Johnson & Johnson Vision Care Inc., Carl Zeiss Meditec AG, Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Senju Pharmaceutical Co. Ltd., MeiraGTx Ltd., Beacon Therapeutics, Clearside Biomedical Inc., Adverum Biotechnologies Inc., Ocugen Inc., GenSight Biologics, Nanoscope Therapeutics Inc., 4D Molecular Therapeutics Inc., Coave Therapeutics.

Global Personalized Ophthalmology Therapies Market Trends and Insights

Major companies operating in the personalized ophthalmology therapies market are focusing on developing advanced solutions, such as one-time intravitreal gene therapies, to minimize patient burden and lower the risk of complications associated with multiple injections. One-time intravitreal gene therapies involve a single injection into the eye’s vitreous cavity to deliver genetic material that addresses or modifies underlying eye disorders, offering lasting treatment effects. For instance, in July 2025, Sanofi, a France-based pharmaceutical and healthcare company, announced the US Food and Drug Administration (FDA) has approved fast track designation for SAR446597. It is a single-dose intravitreal gene therapy designed to treat geographic atrophy (GA) caused by age-related macular degeneration (AMD). It has received fast-track designation to speed up development and regulatory review for serious conditions with unmet needs. The therapy introduces genetic material encoding two antibody fragments that block C1s in the classical complement pathway and factor Bb in the alternative pathway. This dual-action mechanism aims to provide long-lasting complement suppression in the retina, targeting the disease process while minimizing the need for repeated injections.

What Are Latest Mergers And Acquisitions In The Personalized Ophthalmology Therapies Market?

In December 2024, EssilorLuxottica S.A., a France‑based healthcare company, acquired Espansione Group for an undisclosed amount. With this acquisition, EssilorLuxottica aimed to expand its med‑tech portfolio and strengthen its offering of advanced vision‑care instruments and certified medical technologies. Espansione Group S.p.A. is an Italy‑based med‑tech company that specializes in providing personalized ophthalmology therapies.

Regional Outlook

North America was the largest region in the personalized ophthalmology therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Personalized Ophthalmology Therapies Market?

The personalized ophthalmology therapies market includes revenues earned by entities by providing services such as molecular profiling, biomarker identification, patient data integration services, and disease risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Personalized Ophthalmology Therapies Market Report 2026?

The personalized ophthalmology therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the personalized ophthalmology therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.